.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

EULAR

Once Educated, Patients Generally Receptive to Switching to Biosimilars

June 13th 2018

Article

At the European League Against Rheumatism’s Annual European Congress of Rheumatology, held from June 13-16 in Amsterdam, Netherlands, the patient experience with switching to biosimilars from their reference products is a key topic among stakeholders.

Nonmedical Switches Reduce Treatment Costs, Increase Healthcare Utilization

June 13th 2018

Article

During the European League Against Rheumatism’s Annual European Congress of Rheumatology, researchers published findings on the economic impacts of nonmedical switching; while 1 study found that switching to biosimilar infliximab brought down costs without sacrificing efficacy or safety, but another raised concerns about increases in overall healthcare utilization.